About Ginkgo Bioworks
What Ginkgo Bioworks is building
Technologies used at Ginkgo Bioworks
Python
Mysql
Django
AWSCompany culture
Fostering a diverse & inclusive environment
The Ginkgo platform has great potential to have an outsized impact on the world, and we need the people building the technology to be representative of the diverse people our technology will impact.
Encouraging creativity & innovation
Biology is hard to engineer. Guided by the example of our founders, Ginkgo team members are encouraged to be lifelong learners, continuing to take risks and propose ambitious solutions to the world’s problems. What if we could grow everything?
Funding rounds
Total Funding
Last funding round type
Company type
Ginkgo Bioworks news and updates
Ginkgo Bioworks is developing biosecurity capabilities for the African nation on Dec 27th 22'.
Ginkgo Bioworks said on Tuesday that it has signed a memorandum of understanding (MOU) with the government of Botswana to develop and implement new biosecurity capabilities for the African nation.
Dec 20, 2022 | genomeweb.comGinkgo Bioworks launched Ginkgo Enzyme Services on Dec 8th 22'.
Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the launch of Ginkgo Enzyme Services.
Dec 8, 2022 | yahoo.comGinkgo Bioworks sold assets to BTIG Limited in the amount of $100M on Nov 23rd 22'.
Ginkgo Bioworks said on Wednesday before the market open that it has sold $100 million worth of Class A common shares to BTIG.
Nov 16, 2022 | genomeweb.comGinkgo Bioworks sold assets to BTIG Limited in the amount of $100M on Nov 23rd 22'.
Ginkgo Bioworks said on Wednesday before the market open that it has sold $100 million worth of Class A common shares to BTIG.
Nov 16, 2022 | genomeweb.comXpresSpa Group, Inc. partners with Ginkgo Bioworks
During the third quarter of 2022, XpresCheck, in partnership with Ginkgo Bioworks (and in continuation of their support to the CDC’s traveler-based SARS-CoV-2 genomic surveillance program) were awarded a new contract.
Nov 9, 2022 | xwell.comGinkgo Bioworks is developing novel proteins for biomaterials
Bolt Threads, a biotechnology company creating the next generation of advanced materials, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a multi-project collaboration to increase the production efficiency and performance of Bolt's current portfolio as well as expand it by developing novel proteins for biomaterials.
Oct 20, 2022 | biospace.comGinkgo Bioworks partners with Intelligence Advanced Research Projects Activity
In collaboration with IARPA, Ginkgo developed an initial set of computational tools called ENDAR (Engineered Nucleotide Detection and Ranking) that assist trained analysts to identify genetic engineering in next generation sequencing (NGS) datasets.
Oct 16, 2022 | ginkgobioworks.comGinkgo Bioworks partnered with Merck on Oct 12th 22'.
Ginkgo Bioworks, the leading horizontal platform for cell programming, today announced a collaboration with Merck, known as MSD outside the United States and Canada, to engineer up to four enzymes for use as biocatalysts in Merck's active pharmaceutical ingredient (API) manufacturing efforts.
Oct 11, 2022 | clival.comGinkgo Bioworks acquires Circularisbiotech
Ginkgo Bioworks has acquired California-based circular RNA company Circularis Biotechnologies to help improve its gene and cell therapy capacities.
Oct 4, 2022 | insideprecisionmedicine.comGinkgo Bioworks invests into assets : epidemiological data infrastructure assets
Ginkgo Bioworks the leading horizontal platform for cell programming, announced the purchase of certain epidemiological data infrastructure assets from Baktus, Inc., a Delaware-based public benefit corporation.
Sep 27, 2022 | biotechnology.reportGinkgo Bioworks hired Behzad Mahdavi as senior vice president of biopharma manufacturing on Sep 1st 22'.
Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced that Behzad Mahdavi, Ph.D., MBA, has joined as senior vice president of biopharma manufacturing and life sciences tools.
Sep 1, 2022 | yahoo.comGinkgo Bioworks invested into assets : epidemiological data infrastructure assets on Aug 19th 22'.
Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced the purchase of certain epidemiological data infrastructure assets from Baktus, Inc., a Delaware-based public benefit corporation.
Aug 19, 2022 | cmocro.comPhytolon partnered with Ginkgo Bioworks on Feb 28th 22'.
Phytolon, a growing startup company making natural food colorants, announced a partnership today with Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, to produce vibrant cultured food colors via fermentation of yeast.
Jan 1, 2022 | prnewswire.comGinkgo Bioworks acquires Fgen
Ginkgo Bioworks is seeking to further expand its platform for cell programming with the acquisition of the Basel-based startup FGen AG.
Jan 1, 2022 | baselarea.swissGinkgo Bioworks will merge with Soaringeagle on Sep 1st 22'.
When Ginkgo officially merged with Soaring Eagle in September, shares were worth around $12.
Jan 1, 2022 | fiercebiotech.comGinkgo Bioworks acquires Future Genesis, Inc.
Ginkgo Bioworks acquired FGen AG, a Swiss cell s creening tech company.
Jan 1, 2022 | bizjournals.comGinkgo Bioworks invests into Microba in $3.5M
Concurrent with the IPO, Ginkgo Bioworks invested US$3.5 million in Microba, translating to a roughly 4 percent stake in the Brisbane-based company.
Jan 1, 2022 | genomeweb.comGinkgo Bioworks launches 10-K annual report
However, we do know two things are true – Ginkgo Bioworks released their 10-K annual report yesterday, and the stock was up +22% on the same day.
Jan 1, 2022 | nanalyze.comMicroba partnered with Ginkgo Bioworks on Apr 4th 22'.
Microba Life Sciences (ASX: MAP), a precision microbiome science company, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a partnership to identify single-strain, live bacteria product (LBP) candidates against autoimmune diseases.
Jan 1, 2022 | businesswire.comSoaring Eagle Acquisition Corp. merged with Ginkgo Bioworks on Sep 1st 21'.
The team’s most recent SPAC, Soaring Eagle Acquisition, merged last September with Ginkgo Bioworks in a deal valued at a $15 billion, pre-money equity.
Jan 1, 2022 | spacconference.comGinkgo Bioworks launched BiomEdit on Apr 11th 22'.
Elanco Animal Health Incorporated and Ginkgo Bioworks, the leading horizontal platform for cell programming, today announced the launch of BiomEdit, a microbiome innovation company that is expected to discover, develop, and introduce novel probiotics, bioactive molecules, engineered microbial medicines and microbial monitoring services for animal health.
Jan 1, 2022 | beefmagazine.comGinkgo Bioworks is developing novel therapeutics based on the bacterial genus Bacteroides on Apr 12th 22'.
Persephone Biosciences Inc., a synthetic biology company reimagining patient and infant health, and Ginkgo Bioworks (NYSE: DNA ), the leading horizontal platform for cell programming, today announced a collaboration to develop novel therapeutics based on the bacterial genus Bacteroides.
Jan 1, 2022 | prnewswire.comGinkgo Bioworks launches microbiome innovation
US synthetic biology company Ginkgo Bioworks and Elanco Animal Health Incorporated are launching a “microbiome innovation” company that will develop microbiome-based products and services for improved animal health.
Jan 1, 2022 | agfundernews.comGinkgo Bioworks invested into assets : West Sacramento Biologics research and development site in California, United States on Apr 22nd 22'.
Bayer announced on April 22 that the company is pursuing an agreement whereby Ginkgo Bioworks will acquire Bayer’s West Sacramento Biologics research and development site and internal discovery and lead optimization platform.
Jan 1, 2022 | organicgrower.infoGinkgo Bioworks is developing animal-free egg proteins
Evo Foods and Ginkgo Bioworks have announced they are working together to develop animal-free egg proteins.
Jan 1, 2022 | vegconomist.comGinkgo Bioworks launched cell development kit for protein production on Apr 12th 22'.
Additionally, Ginkgo recently launched its cell development kit for protein production, which is expected to scale at a rapid pace.
Jan 1, 2022 | investorplace.comEvo Foods partners with Ginkgo Bioworks
Indian plant-based egg startup Evo Foods has announced it is partnering with Ginkgo Bioworks to create new ingredients for its products.
Jan 1, 2022 | greenqueen.com.hkGinkgo Bioworks partners with Concentric by Ginkgo
The air sampling is in partnership with Concentric by Ginkgo, the biosecurity and public health arm of Ginkgo Bioworks, Inc.
Jan 1, 2022 | almanacnews.comBitome, Inc. sells assets to Ginkgo Bioworks
Ginkgo Bioworks ( NYSE: DNA ) has acquired certain assets from Boston-based Bitome for an undisclosed financial terms.
Jan 1, 2022 | seekingalpha.comGinkgo Bioworks partnered with Novo Nordisk A/S on Jun 7th 22'.
Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration with Novo Nordisk, a leading global healthcare company, to create novel expression hosts for pharmaceutical products.
Jan 1, 2022 | ksn.comGinkgo Bioworks received financing of $90M in Series A on Feb 1st 19'.
It’s the largest Series A in food tech history: Ginkgo Bioworks today announced the $90 million launch of Motif Ingredients, a spin-out company that aims to provide next-generation alternative proteins and other ingredients to food companies worldwide.The new company will leverage Ginkgo’s biological engineering platform to create novel food solutions that give consumers greater choice without compromising taste or nutrition.
Jan 1, 2022 | synbiobeta.comGinkgo Bioworks launched Motif Foodworks on Feb 1st 19'.
In February 2019 Ginkgo launched Motif Foodworks with a $90 million Series A, the largest in food tech history.
Jan 1, 2022 | synbiobeta.comGinkgo Bioworks acquires Bitome, Inc.
In recent months, Ginkgo announced collaborations with a slew of companies and acquired Bitome, which operates as a cell culture media monitoring company.
Jan 1, 2022 | investorplace.comGinkgo Bioworks launched Sustainability Report on Jul 14th 22'.
Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today published its inaugural Sustainability Report.
Jan 1, 2022 | cmocro.comGinkgo Bioworks is developing horizontal platform
Ginkgo has chosen to develop a horizontal platform that can be used by other companies to develop products, touting themselves as the AWS of synthetic biology.
Jan 1, 2022 | seekingalpha.comGinkgo Bioworks acquires Zymergen Inc.
In case all of that isn’t enough to absorb, Ginkgo Bioworks has also agreed to acquire Zymergen.
Jan 1, 2022 | investorplace.comGinkgo Bioworks launches cell programming project
Cell programming company Ginkgo Bioworks has launched a new cell programming project as part of a broader collaboration with Japanese company Sumitomo Chemical Co., Ltd.
Jan 1, 2022 | labiotech.euPersephone Biosciences partnered with Ginkgo Bioworks on Apr 1st 22'.
Then in April 2022, Persephone announced a collaboration with Ginkgo Bioworks to enable the synthetic biology tools needed to develop the next generation of microbial therapies.
Jan 1, 2022 | gritdaily.comGinkgo Bioworks hired Kathy Hopinkah Hannan as board member on Aug 5th 22'.
Ginkgo Bioworks (NYSE: DNA), also added a board member this week, announcing the appointment of Kathy Hopinkah Hannan, PhD, CPA.
Jan 1, 2022 | marketscreener.comGinkgo Bioworks partners with Sumitomochemical
Boston biotech outfit Ginkgo Bioworks has launched a project with Japanese firm Sumitomo Chemical to produce sustainable molecules for the personal care and cosmetics industries.
Jan 1, 2022 | personalcaremagazine.comGinkgo Bioworks is developing toolkit needed to develop novel microbial therapeutics on Apr 1st 22'.
In April, Persephone announced it was collaborating with Boston-based Ginkgo Bioworks to develop a toolkit needed to develop novel microbial therapeutics.
Jan 1, 2022 | sdbj.comGinkgo Bioworks partners with Synlogic
Ginkgo announced a new drug candidate for gout with Synlogic (NASDAQ: SYBX ).
Jan 1, 2022 | investorplace.comBiotechnology partners with Ginkgo Bioworks
Biotechnology is excited about its plans to partner with Ginkgo to bring cutting-edge biosecurity capabilities to Rwanda across various sectors including health and agriculture.
Jan 1, 2022 | biotechnology.reportArcaea, a Company Launched on the Ginkgo Bioworks Platform, Announces $78M Series A To Build a New Foundation For the Beauty Industry through Expressive Biology
Arcaea (Ar-kay-uh), a company launched on the Ginkgo Bioworks (NYSE: DNA) Platform, today announced its $78M Series A to build a new, regenerative future for the beauty industry through expressive biology—where biology is used as a creative tool for self-expression.
Oct 27, 2021 | PR NewswireSelecta Biosciences and Ginkgo Bioworks Announce Partnership to Advance Treatments for Orphan and Rare Diseases
Selecta Biosciences, Inc. (Nasdaq: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration to design novel and improved enzymes with transformative therapeutic potential to advance treatments for orphan and rare diseases.
Oct 26, 2021 | PR NewswireSelecta Biosciences and Ginkgo Bioworks Announce Partnership to Advance Treatments for Orphan and Rare Diseases
Leveraging Ginkgo's cell programming platform and Selecta's ImmTOR platform to create potentially transformative enzymatic therapies
Oct 26, 2021 | WBRCT. Rowe Price Group invests into Ginkgo Bioworks in $900M
Ginkgo has raised more than $900 million in venture funding from investors including Bill Gates, General Atlantic, T. Rowe Price and Viking Global Investors.
Jan 1, 2021 | nytimes.comBlock & Leviton LLP files suit against Ginkgo Bioworks
Block & Leviton announces that a class action lawsuit has been filed against Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) for potential securities law violations.
Jan 1, 2021 | globenewswire.comCorteva, Inc. partnered with Ginkgo Bioworks on Apr 1st 21'.
For instance, In April 2021, Corteva Agriscience, a US-based agricultural chemical, and seed company collaborated with a USA-based biotechnology company Ginkgo Bioworks.
Jan 1, 2021 | einnews.comGinkgo Bioworks receives financing of $900M in funding
Ginkgo has raised more than $800 million in venture capital because of its ability to genetically program organisms for customers in markets as varied as flavors and fragrances and pharmaceuticals.
Jan 1, 2020 | wsj.comGinkgo Bioworks received financing of $70M in funding on Apr 30th 20'.
Ginkgo Bioworks, a Boston, MA-based company that uses biology to grow products, received a $70M investment.
Jan 1, 2020 | finsmes.comGinkgo Bioworks received financing of $350M on Oct 9th 19'.
(Reuters) - Biotechnology start-up Ginkgo Bioworks said on Wednesday that it had raised a $350 million fund to more easily invest in spinout ventures that use its bio-engineering technology in a variety of industries that are just starting to use cutting edge biology.
Jan 1, 2019 | reuters.comGinkgo Bioworks receives financing of $719M
Including this round, Ginkgo Bioworks has raised a total of $719 million.
Jan 1, 2019 | pulse2.comGinkgo Bioworks received financing of $290M in Series E financing round on Sep 19th 19'.
In September, Ginkgo announced a $290 million funding round that pegged its valuation at as much as $4.8 billion.
Jan 1, 2019 | xconomy.comGinkgo Bioworks receives financing of $429M
Ginkgo has raised $429 million from investors including Viking Global Investors and Bill Gates' investment company Cascade Investment.
Jan 1, 2019 | cnbc.comGinkgo Bioworks received financing of $100M in fundraising round on Jan 1st 17'.
In 2017, Bayer AG and Ginkgo Bioworks announced a $100 million fundraising round for its joint venture focusing on microbes for nitrogen fertilizer.
Jan 1, 2018 | arabianbusiness.comGinkgo Bioworks partners with Kerry Group
Ginkgo will work with Kerry on more efficient production of specialty enzymes used in food.
Jan 1, 2017 | prnewswire.comGinkgo Bioworks received financing of $275M in Series D funding round on Dec 12th 17'.
Ginkgo Bioworks, a genetic engineering company, said Wednesday that it has raised another $275 million and opened a third laboratory in Boston’s Seaport District.
Jan 1, 2017 | starthub.org